Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
259 hedge funds and large institutions have $6.02B invested in Blueprint Medicines in 2023 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 98 reducing their positions, and 17 closing their positions.
253% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 17
85% more capital invested
Capital invested by funds: $3.25B → $6.02B (+$2.77B)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
28% more call options, than puts
Call options by funds: $131M | Put options by funds: $102M
18% more funds holding
Funds holding: 220 → 259 (+39)
0.65% more ownership
Funds ownership: 106.69% → 107.34% (+0.65%)
32% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 98
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$128M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$93.9M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$64.6M |
| 4 |
Man Group
London,
United Kingdom
|
+$24.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$22.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$113M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$55.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$52.1M |
| 4 |
Millennium Management
New York
|
-$49M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$36M |
BPMC Hedge Fund Activity: Q4 2023 in Review
259 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2023, worth a combined $6.02B — up 85% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new BPMC positions and 17 closed out — a net gain of 43 holders — while 67 added to existing stakes and 98 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $128M. The largest seller was Fidelity Investments, cutting an estimated $113M.
- 259 institutional investors held Blueprint Medicines (BPMC) as of Q4 2023, up from 220 in Q3 2023.
- Funds reported $6.02B of Blueprint Medicines stock for Q4 2023, up 85% quarter-over-quarter.
- 60 funds opened new Blueprint Medicines positions in Q4 2023 and 17 closed out, a net change of +43 holders.
- The largest Blueprint Medicines buyer in Q4 2023 was Morgan Stanley, an estimated $128M added.
- The largest Blueprint Medicines seller in Q4 2023 was Fidelity Investments, an estimated $113M sold.
Based on aggregated 13F filings for Q4 2023.